Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience

Nina Asrini Noor,1 Syukri Mustafa,1,2 Widya Artini1,2 1Ophthalmology Department, 2Glaucoma Division, Ophthalmology Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia Purpose: To evaluate the outcome of glaucoma drainage device (GDD) implantation with and without intravitreal bevac...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Noor NA, Mustafa S, Artini W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	neovascular glaucoma glaucoma drainage device bevacizumab Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8e4a4f16b1f24babb40ac6c94ebefc70
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8e4a4f16b1f24babb40ac6c94ebefc70
record_format	dspace
spelling	oai:doaj.org-article:8e4a4f16b1f24babb40ac6c94ebefc702021-12-02T02:35:46ZGlaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience1177-5483https://doaj.org/article/8e4a4f16b1f24babb40ac6c94ebefc702017-08-01T00:00:00Zhttps://www.dovepress.com/glaucoma-drainage-device-implantation-with-adjunctive-intravitreal-bev-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Nina Asrini Noor,1 Syukri Mustafa,1,2 Widya Artini1,2 1Ophthalmology Department, 2Glaucoma Division, Ophthalmology Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia Purpose: To evaluate the outcome of glaucoma drainage device (GDD) implantation with and without intravitreal bevacizumab (IVB) injection in treating neovascular glaucoma (NVG) at Cipto Mangunkusumo Hospital Jakarta, Indonesia.Patients and methods: This retrospective study involved 39 eyes with NVG which underwent GDD implantation between 2012 and 2014. Thirty eyes underwent GDD implantation alone (control group) while 9 eyes underwent GDD implantation and IVB injection (IVB group). Visual acuity (VA), intraocular pressure (IOP), number of antiglaucoma medications, and success rate were compared between groups.Results: There were no significant differences in preoperative characteristics. On the last visit, VA was 2.6 (0.2–4.0) logMAR in the control group and 2.3 (0.4–4.0) logMAR in the IVB group (P=0.97). In the control group, final VA was significantly worse compared to initial VA (P<0.01), while in IVB group VA was apparently stable (P=0.24). Final IOP was 16.3±10.3 mmHg in the control group and 12.0 (2.0–49.0) mmHg in IVB group (P=0.40). The number of antiglaucoma medications was similar between groups (P=0.57). Surgical success rate in the IVB group (66.7%) was better than the control group (56.7%), but this difference was not statistically significant (P=0.71). Kaplan–Meier survival analysis showed the probability of success 37 months after surgery as 53.6% in the IVB group and 31.6% in the control group. No significant difference was found between the groups (P=0.45).Conclusion: In cases of NVG, GDD combined with IVB could maintain VA compared to GDD alone. However, there were no significant differences in final IOP, number of antiglaucoma medications, and surgical success rate. Keywords: Ahmed glaucoma valve, Baerveldt implant, glaucoma surgery, vascular endothelial growth factor, VEGF Noor NAMustafa SArtini WDove Medical Pressarticleneovascular glaucomaglaucoma drainage devicebevacizumabOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 1417-1422 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	neovascular glaucoma glaucoma drainage device bevacizumab Ophthalmology RE1-994
spellingShingle	neovascular glaucoma glaucoma drainage device bevacizumab Ophthalmology RE1-994 Noor NA Mustafa S Artini W Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
description	Nina Asrini Noor,1 Syukri Mustafa,1,2 Widya Artini1,2 1Ophthalmology Department, 2Glaucoma Division, Ophthalmology Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia Purpose: To evaluate the outcome of glaucoma drainage device (GDD) implantation with and without intravitreal bevacizumab (IVB) injection in treating neovascular glaucoma (NVG) at Cipto Mangunkusumo Hospital Jakarta, Indonesia.Patients and methods: This retrospective study involved 39 eyes with NVG which underwent GDD implantation between 2012 and 2014. Thirty eyes underwent GDD implantation alone (control group) while 9 eyes underwent GDD implantation and IVB injection (IVB group). Visual acuity (VA), intraocular pressure (IOP), number of antiglaucoma medications, and success rate were compared between groups.Results: There were no significant differences in preoperative characteristics. On the last visit, VA was 2.6 (0.2–4.0) logMAR in the control group and 2.3 (0.4–4.0) logMAR in the IVB group (P=0.97). In the control group, final VA was significantly worse compared to initial VA (P<0.01), while in IVB group VA was apparently stable (P=0.24). Final IOP was 16.3±10.3 mmHg in the control group and 12.0 (2.0–49.0) mmHg in IVB group (P=0.40). The number of antiglaucoma medications was similar between groups (P=0.57). Surgical success rate in the IVB group (66.7%) was better than the control group (56.7%), but this difference was not statistically significant (P=0.71). Kaplan–Meier survival analysis showed the probability of success 37 months after surgery as 53.6% in the IVB group and 31.6% in the control group. No significant difference was found between the groups (P=0.45).Conclusion: In cases of NVG, GDD combined with IVB could maintain VA compared to GDD alone. However, there were no significant differences in final IOP, number of antiglaucoma medications, and surgical success rate. Keywords: Ahmed glaucoma valve, Baerveldt implant, glaucoma surgery, vascular endothelial growth factor, VEGF
format	article
author	Noor NA Mustafa S Artini W
author_facet	Noor NA Mustafa S Artini W
author_sort	Noor NA
title	Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
title_short	Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
title_full	Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
title_fullStr	Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
title_full_unstemmed	Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
title_sort	glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/8e4a4f16b1f24babb40ac6c94ebefc70
work_keys_str_mv	AT noorna glaucomadrainagedeviceimplantationwithadjunctiveintravitrealbevacizumabinneovascularglaucoma3yearexperience AT mustafas glaucomadrainagedeviceimplantationwithadjunctiveintravitrealbevacizumabinneovascularglaucoma3yearexperience AT artiniw glaucomadrainagedeviceimplantationwithadjunctiveintravitrealbevacizumabinneovascularglaucoma3yearexperience
_version_	1718402362545012736

Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience

Ejemplares similares